Maravai LifeSciences Holdings, Inc. (MRVI) stock
MRVINasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30170% above fair value
$7.28−0.12 (-1.62%)
Close on Nov 17, 2026Market cap $1.89BP/E –Yield –
Maravai LifeSciences total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Maravai LifeSciences's total debt was $147.11M at Jun 30, 2026. For fiscal 2025 it was $291.77M, down 1.4% from the year before. The highest annual figure on record is $534.61M in fiscal 2020.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $291.77M | -1.4% |
| FY2024 | Dec 31, 2024 | $295.93M | -43.5% |
| FY2023 | Dec 31, 2023 | $524.15M | -0.6% |
| FY2022 | Dec 31, 2022 | $527.44M | -0.6% |
| FY2021 | Dec 31, 2021 | $530.59M | -0.8% |
| FY2020 | Dec 31, 2020 | $534.61M | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $147.11M | -49.9% |
| Q1 FY2026 | Mar 31, 2026 | $241.01M | -18.3% |
| Q4 FY2025 | Dec 31, 2025 | $291.77M | -1.4% |
| Q3 FY2025 | Sep 30, 2025 | $292.82M | -43.9% |
| Q2 FY2025 | Jun 30, 2025 | $293.88M | -43.8% |
| Q1 FY2025 | Mar 31, 2025 | $294.94M | -43.6% |
| Q4 FY2024 | Dec 31, 2024 | $295.93M | -43.5% |
| Q3 FY2024 | Sep 30, 2024 | $521.72M | -0.6% |
| Q2 FY2024 | Jun 30, 2024 | $522.52M | -0.6% |
| Q1 FY2024 | Mar 31, 2024 | $523.33M | -0.6% |
| Q4 FY2023 | Dec 31, 2023 | $524.15M | -0.6% |
| Q3 FY2023 | Sep 30, 2023 | $524.96M | -0.6% |
| Q2 FY2023 | Jun 30, 2023 | $525.78M | -0.6% |
| Q1 FY2023 | Mar 31, 2023 | $526.60M | -0.6% |
| Q4 FY2022 | Dec 31, 2022 | $527.44M | -0.6% |
| Q3 FY2022 | Sep 30, 2022 | $528.26M | -0.6% |
| Q2 FY2022 | Jun 30, 2022 | $529.10M | -0.7% |
| Q1 FY2022 | Mar 31, 2022 | $529.94M | -0.7% |
| Q4 FY2021 | Dec 31, 2021 | $530.59M | -0.8% |
| Q3 FY2021 | Sep 30, 2021 | $531.58M | – |
| Q2 FY2021 | Jun 30, 2021 | $532.58M | – |
| Q1 FY2021 | Mar 31, 2021 | $533.59M | – |
| Q4 FY2020 | Dec 31, 2020 | $534.61M | – |
See a number that looks wrong?